Docket No.: 04703/0202222-US0

AMENDMENTS TO THE SPECIFICATION

Please replace ¶ 4 of the published specification with the following amended paragraph:

-- Recently, allergic diseases are treated mainly with antagonists to chemical mediators, such as antihistamine, and steroids used as anti-inflammatory agents. However, both of these agents merely provide symptomatic therapy, and steroids inhibit the overall immune response, resulting in side effects. Alternatively, agents for inhibiting release of chemical mediators by inhibition of degranulation are also used, but no fundamental therapeutic agents have [[not]] been found for specifically reducing the IgE antibody, which is the major factor of allergy development. --